---
title: "SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm"
description: "The Schall Law Firm has issued a shareholder action alert for investors in Akero Therapeutics, Inc. The class action lawsuit alleges violations of securities laws and misleading statements by the comp"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/203023313.md"
published_at: "2024-04-29T00:21:13.000Z"
---

# SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm

> The Schall Law Firm has issued a shareholder action alert for investors in Akero Therapeutics, Inc. The class action lawsuit alleges violations of securities laws and misleading statements by the company. Investors who suffered losses are encouraged to contact the law firm before June 25, 2024, to participate in the case.

LOS ANGELES, April 28, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. (“Akero” or “the Company”) (NASDAQ: AKRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.  

Investors who purchased the Company’s securities between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before June 25, 2024.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. 20% of the patients enrolled in Akero’s SYMMETRY study suffered from cryptogenic cirrhosis and did not have definitive NASH at baseline. These patients did not have biopsy-proven compensated cirrhosis. The SYMMETRY study excluded these patients when calculating the NASH resolution secondary endpoints. The Company influenced the study’s results and increased its likelihood of failing to reach its primary endpoint by introducing confounding factors to the study. The SYMMETRY study failed to align with FDA guidance by not ruling out potential causes for each patients’ cirrhosis. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Akero, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

**CONTACT:**

The Schall Law Firm  
Brian Schall, Esq.,  
www.schallfirm.com  
Office: 310-301-3335  
info@schallfirm.com

**SOURCE:**

The Schall Law Firm

### Related Stocks

- [AKRO.US - Akero Therapeutics](https://longbridge.com/en/quote/AKRO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| ACROBiosystems 在 bioSeedin 的 JPM Spotlight 會議上推動創新，並戰略性地支持全球合作伙伴關係的建立 | ACROBiosystems 參加了於 1 月 11 日舉行的 BIOSeedin 冬季創新合作峯會，此次峯會在舊金山的 J.P. Morgan 2026 之前舉行。此次活動以 “創新資產的全球匹配” 為主題，匯聚了跨國製藥公司、投資者和生 | [Link](https://longbridge.com/en/news/275692064.md) |
| Rakovina Therapeutics 任命 Kim Oishi 為首席執行官和董事 | Rakovina Therapeutics Inc. 已任命 Kim Oishi 為首席執行官和董事。Dennis Brown 已辭去董事會職務，但將繼續擔任科學顧問委員會主席。Al DeLucrezia 也已辭去董事會職務，將繼續擔任顧問 | [Link](https://longbridge.com/en/news/273889407.md) |
| FDA 授予拜耳的 OpCT-001 用於治療視網膜色素變性的孤兒藥資格 | 拜耳公司和 BlueRock Therapeutics 宣佈，美國食品藥品監督管理局（FDA）已授予其研究性細胞療法 OpCT-001 孤兒藥資格，用於治療視網膜色素變性。這種療法源自誘導多能幹細胞，目前正在進行針對主要光感受器疾病的 1/ | [Link](https://longbridge.com/en/news/273335268.md) |
| Aker BioMarine 第四季度調整後的息税折舊及攤銷前利潤（EBITDA）增長 66%，達到 1060 萬美元 | Aker BioMarine ASA 報告了 2025 年第四季度的收入為 5520 萬美元，同比增長 6%，調整後的 EBITDA 上升 66% 至 1060 萬美元。2025 財年的收入達到 2.181 億美元，同比增長 10%，調整後 | [Link](https://longbridge.com/en/news/275706260.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.